Abstract
The decision to use psychoactive medications in children and adolescents is not taken lightly by parents or clinicians. Medications are often utilized after periods of behavioral therapy or psychotherapeutic approaches have failed to ameliorate adequately the presenting symptoms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abramowicz M: Sudden death in children treated with a tricyclic antidepressant. Med Lett Drugs Ther 32: 53, 1990.
Riddle MA, Nelson JC, Kleinman CS, et al: Sudden death in children receiving Norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30: 104–108, 1991.
Gittelman-Klein R, Spitzer RL, Cantwell D: Diagnostic classifications and psychopharmacological indications, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978, pp 136–167.
Campbell M, Palij, M: Measurement of side effects including tardive dyskinesia, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 1063–1066, 1985.
Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21 (4), 1985.
Guy W: Dosage Record and Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 223–244.
Guy W: Treatment Emergent Symptoms Scale—Write-In, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 341–345.
Guy W: Subjects Treatment Emergent Symptoms Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 347–350.
Guy W: Abnormal Involuntary Movement Scale, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 534–537.
Campbell M, Green WH, Deutsch SI: Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985, pp 11–42.
Guy W: Physical and Neurological Examination for Soft Signs, ECDEU Assessment Manual for Psychopharmacology (Revised). US Department of Health, Education and Human Welfare publication (ADM) 76-338, 1976, pp 383–406.
Denckla MB: Revised neurological examination for subtle signs, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 773–789, 1985.
Sleator EK: Measurement of compliance, Psychopharmacology Bulletin: Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research. National Institute of Mental Health, 21(4): 1089–1093, 1985.
Khan AU: Biochemical profile of depressed adolescents. J Am Acad Child Adolesc Psychiatry 6: 873–878, 1987.
Doherty M, Madansky D, Kraft J, et al: Cortisol dynamics and test performance of the dexamethasone suppression test in 97 psychiatrically hospitalized children aged 3-16 years. J Am Acad Child Psychiatry 25(3): 400–408, 1986.
Klee S, Garfinkel B: Identification of depression in children and adolescents: The role of the dexamethasone suppression test. J Am Acad Child Psychiatry 23: 410–415, 1984.
Kinsbourne M: Disorders of mental development, in Menkes JH (ed): Textbook of Child Neurology, ed 3. Philadelphia, Lea & Febiger, 1985, pp 764–801.
Raj A, Sheehan D: Medical evaluation of panic attacks. J Clin Psychiatry 48: 309–313, 1987.
Zametkin A, Rapoport J: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J. Am Acad Child Adolesc Psychiatry 26: 676–686, 1987.
Bowden CL, Deutsch CK, Swanson JM: Plasma dopamine beta hydroxylase and platelet monoamine oxidase in attention deficit disorder and conduct disorder. J Am Acad Child Adolesc Psychiatry 27: 171–174, 1988.
Kruesi MJP: Cruelty to animals and CSF 5-HIAA. Psychiatry Res 28: 115–116, 1989.
Kruesi MJP, Linnoila M, Rapoport JL, et al: Carbohydrate craving, conduct disorder and low CSF 5-HIAA. Psychiatry Res 16: 83–86, 1985.
Kruesi MJP, Rapoport JL, Hamburger S, et al: CSF monoamine metabolites, aggression and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry 47: 419–426, 1990.
Diederich N, Ackerman R, Jurgens R, et al: Early involvement of the nervous system by human immune deficiency virus (HIV): A study of 79 patients. Eur Neurol 28: 93–103, 1988.
Leckman JF, Weissman MM, Pauls DL: Family-genetic studies and identification of valid diagnostic categories in adult and child psychiatry, Br J Psychiatry 151: 39–44, 1987.
Walzer S, et al: A method for the longitudinal study of behavioral development in infants and children: The early development of XXY children. J Child Psychol Psychiatry 19: 213–229, 1978.
Ratcliffe SG, Field MAS: Emotional disorder of XYY children: Four case reports. J Child Psychol Psychiatry 23: 401–406, 1982.
Nielsen J, Pelsen B, Sorenson K: Follow-up of 30 Klinefelter males treated with testosterone. Clin Genet 33: 262–269, 1988.
Dening T, Berrios G: Wilson’s disease: Psychiatric symptoms in 195 cases. Arch Gen Psychiatry 46: 1126–1134, 1989.
Courchesne E, Yeung-Courchesne R, Press G, et al: Hypoplasia of cerebellar vermal lobules VI and VII in autism. N Engl J Med 318: 1349–1354, 1988.
Chugani H: Personal communication.
Gwirtsman HE, Kaye WH, George DT, et al: Hyperamylasemia and its relationship to binge-purge episodes: Development of a clinically relevant laboratory test. J Clin Psychiatry 50(6): 196–204, 1989.
Schoonover SC: Introduction: The practice of pharmacotherapy, in Bassuk EL, Schoonover SC, Gelenberg AJ (ed): The Practitioner’s Guide to Psychoactive Drugs, ed 2. New York, Plenum Press, 1983, pp 10–11.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Zametkin, A.J., Yamada, E.M. (1993). Monitoring and Measuring Drug Effects. I. Physical Effects. In: Werry, J.S., Aman, M.G. (eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2884-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2884-5_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-44389-3
Online ISBN: 978-1-4615-2884-5
eBook Packages: Springer Book Archive